English
Insider transactions
EDGARMBX Biosciences, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 1 transactions, 18,500 shares
- Sum of shares × price per share: 525,662.7
- Open-market sales (code S)
- 7 transactions, 76,477 shares
- Sum of shares × price per share: 3,022,965.66
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–37 of 37
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-10 Filed 2026-11-12 | Hoerter Steven L. Director · Officer: Chairman, President and CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 4,893 | 54.82 | 268,234.26Derived: shares × price per share. Exact value 268234.26. | 78,045 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-457015 Read from the filing’s XML Dispute this row |
| 2026-11-04 Filed 2026-11-05 | Azoulay Salomon Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 373 | 53.96 | 20,127.08Derived: shares × price per share. Exact value 20127.08. | 14,026 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-449832 Read from the filing’s XML Dispute this row |
| 2026-10-20 Filed 2026-10-22 | Radovich Peter Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 18,200 | 0 | — | 18,200 | Direct (D) | No | F1
| Open filing 0001193125-26-428390 Read from the filing’s XML Dispute this row |
| 2026-08-04 Filed 2026-08-05 | Azoulay Salomon Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 370 | 65.77 | 24,334.9Derived: shares × price per share. Exact value 24334.90. | 14,399 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-335373 Read from the filing’s XML Dispute this row |
| 2026-08-03 Filed 2026-08-04 | Hoerter Steven L. Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 71,000 | 0 | — | 82,938 | Direct (D) | No | F1
| Open filing 0001193125-26-331639 Read from the filing’s XML Dispute this row |
| 2026-08-03 Filed 2026-08-04 | Hoerter Steven L. Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 331,000 | 0 | — | 331,000 | Direct (D) | No | F3
| Open filing 0001193125-26-331639 Read from the filing’s XML Dispute this row |
| 2026-08-03 Filed 2026-08-04 | Smither John W Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 28,000 | 0 | — | 28,000 | Direct (D) | No | F1
| Open filing 0001193125-26-331642 Read from the filing’s XML Dispute this row |
| 2026-08-03 Filed 2026-08-04 | Smither John W Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 130,000 | 0 | — | 130,000 | Direct (D) | No | F2
| Open filing 0001193125-26-331642 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-05 | Aynechi Tiba Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 12,500 | 0 | — | 12,500 | Direct (D) | No | F1
| Open filing 0001193125-26-258420 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-05 | Ryder Steven Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 12,500 | 0 | — | 12,500 | Direct (D) | No | F1
| Open filing 0001193125-26-258422 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-05 | Mathers Edward T Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 12,500 | 0 | — | 12,500 | Direct (D) | No | F1
| Open filing 0001193125-26-259236 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-05 | Stelzer Laurie Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 12,500 | 0 | — | 12,500 | Direct (D) | No | F1
| Open filing 0001193125-26-258432 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-05 | Hoerter Steven L. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 12,500 | 0 | — | 12,500 | Direct (D) | No | F2
| Open filing 0001193125-26-258429 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-05 | Heron Patrick J Director · 10% owner | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 12,500 | 0 | — | 12,500 | Direct (D) | No | F1
| Open filing 0001193125-26-258435 Read from the filing’s XML Dispute this row |
| 2026-06-04 Filed 2026-06-05 | Pescovitz Ora H. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 12,500 | 0 | — | 12,500 | Direct (D) | No | F1
| Open filing 0001193125-26-258436 Read from the filing’s XML Dispute this row |
| 2026-05-08 Filed 2026-05-11 | Azoulay Salomon Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 55,000 | 10.46 | 575,300Derived: shares × price per share. Exact value 575300.00. | 69,769 | Direct (D) | Yes | F1
| Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row |
| 2026-05-08 Filed 2026-05-11 | Azoulay Salomon Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 55,000 | 38.38 | 2,110,900Derived: shares × price per share. Exact value 2110900.00. | 14,769 | Direct (D) | Yes | F1, F2
| Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row |
| 2026-05-08 Filed 2026-05-11 | Azoulay Salomon Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 15,003 | 16 | 240,048Derived: shares × price per share. Exact value 240048. | 29,772 | Direct (D) | Yes | F1
| Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row |
| 2026-05-08 Filed 2026-05-11 | Azoulay Salomon Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 15,003 | 38.30 | 574,614.9Derived: shares × price per share. Exact value 574614.90. | 14,769 | Direct (D) | Yes | F1, F3
| Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row |
| 2026-05-08 Filed 2026-05-11 | Azoulay Salomon Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 55,000 | 0 | — | 194,540 | Direct (D) | Yes | F4
| Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row |
| 2026-05-08 Filed 2026-05-11 | Azoulay Salomon Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 15,003 | 0 | — | 30,008 | Direct (D) | Yes | F5
| Open filing 0001193125-26-216704 Read from the filing’s XML Dispute this row |
| 2026-05-06 Filed 2026-05-08 | Hawryluk P. Kent Director · Officer: President CEO | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 607 | 29.54 | 17,930.78Derived: shares × price per share. Exact value 17930.78. | 727,667 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-214574 Read from the filing’s XML Dispute this row |
| 2026-05-06 Filed 2026-05-08 | Azoulay Salomon Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 231 | 29.54 | 6,823.74Derived: shares × price per share. Exact value 6823.74. | 14,769 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-214582 Read from the filing’s XML Dispute this row |
| 2026-05-01 Filed 2026-05-04 | Hoerter Steven L. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 11,938 | 0 | — | 11,938 | Direct (D) | No | F1
| Open filing 0001193125-26-202615 Read from the filing’s XML Dispute this row |
| 2026-05-01 Filed 2026-05-04 | Hoerter Steven L. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 74,249 | 0 | — | 74,249 | Direct (D) | No | F3
| Open filing 0001193125-26-202615 Read from the filing’s XML Dispute this row |
| 2026-03-13 Filed 2026-03-16 | Hawryluk P. Kent Director · Officer: President CEO | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 18,500 | 28.4142 | 525,662.7Derived: shares × price per share. Exact value 525662.7000. | 486,777 | Indirect (I) By Trust | No | F1, F2
| Open filing 0001193125-26-107268 Read from the filing’s XML Dispute this row |
| 2026-02-26 Filed 2026-02-27 | Hawryluk P. Kent Director · Officer: President CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 28,768 | 16.00 | 460,288Derived: shares × price per share. Exact value 460288.00. | 728,274 | Direct (D) | No | — | Open filing 0001193125-26-082562 Read from the filing’s XML Dispute this row |
| 2026-02-26 Filed 2026-02-27 | Hawryluk P. Kent Director · Officer: President CEO | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 28,768 | 0 | — | 91,668 | Direct (D) | No | F2
| Open filing 0001193125-26-082562 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-03 | Azoulay Salomon Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 15,000 | 0 | — | 15,000 | Direct (D) | No | F1
| Open filing 0001193125-26-035587 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-03 | Azoulay Salomon Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 70,000 | 0 | — | 70,000 | Direct (D) | No | F2
| Open filing 0001193125-26-035587 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-03 | Hawryluk P. Kent Director · Officer: President CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 35,250 | 0 | — | 699,506 | Direct (D) | No | F1
| Open filing 0001193125-26-035582 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-03 | Hawryluk P. Kent Director · Officer: President CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 164,500 | 0 | — | 164,500 | Direct (D) | No | F3
| Open filing 0001193125-26-035582 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-03 | Bartram Richard Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 15,000 | 0 | — | 15,000 | Direct (D) | No | F1
| Open filing 0001193125-26-035584 Read from the filing’s XML Dispute this row |
| 2026-02-02 Filed 2026-02-03 | Bartram Richard Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 70,000 | 0 | — | 70,000 | Direct (D) | No | F2
| Open filing 0001193125-26-035584 Read from the filing’s XML Dispute this row |
| 2026-01-20 Filed 2026-01-22 | Stelzer Laurie Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 32,000 | 0 | — | 32,000 | Direct (D) | No | F1
| Open filing 0001193125-26-018702 Read from the filing’s XML Dispute this row |
| 2025-11-22 Filed 2026-04-22 | Hoerter Steven L. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 0 | 0 | — | 0 | Direct (D) | No | F1, F2
| Open filing 0001193125-26-168530 Read from the filing’s XML Dispute this row |
| 2025-11-22 Filed 2025-11-25 | Hoerter Steven L. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 8,000 | 0 | — | 8,000 | Direct (D) | No | F1
| Open filing 0001193125-25-294675 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.
Showing 1–50 of 200
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| FMR LLC Partly reported under another manager | 7,368,420 SH | 431,936,786 dollars | Higher by 2,045,535 Prior quarter: 5,322,885 | Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row |
| Frazier Life Sciences Management, L.P. | 6,652,013 SH | 389,941,002 dollars | Unchanged Prior quarter: 6,652,013 | Open filing 0001892134-26-000007 Filed 2026-11-16 Dispute this row |
| WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager | 5,164,535 SH | 302,745,043 dollars | Higher by 187,012 Prior quarter: 4,977,523 | Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row |
| Paradigm Biocapital Advisors LP | 3,772,885 SH | 221,166,519 dollars | Higher by 1,264,870 Prior quarter: 2,508,015 | Open filing 0001855655-26-000020 Filed 2026-11-16 Dispute this row |
| NEA Management Company, LLC | 3,614,486 SH | 211,881,169 dollars | Unchanged Prior quarter: 3,614,486 | Open filing 0001072613-26-000901 Filed 2026-11-16 Dispute this row |
| BlackRock, Inc. Partly reported under another manager | 3,473,447 SH | 203,613,464 dollars | Higher by 149,775 Prior quarter: 3,323,672 | Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row |
| ORBIMED ADVISORS LLC | 3,074,853 SH | 180,247,883 dollars | Lower by 353,883 Prior quarter: 3,428,736 | Open filing 0001172661-26-005349 Filed 2026-11-16 Dispute this row |
| NVP ASSOCIATES, LLC | 2,136,335 SH | 125,231,958 dollars | Unchanged Prior quarter: 2,136,335 | Open filing 0001545692-26-000013 Filed 2026-11-13 Dispute this row |
| Polar Capital Holdings Plc Partly reported under another manager | 1,603,582 SH | 94,001,977 dollars | Lower by 4,932 Prior quarter: 1,608,514 | Open filing 0001172661-26-005169 Filed 2026-11-16 Dispute this row |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,430,897 SH | 83,879,182 dollars | Lower by 46,491 Prior quarter: 1,477,388 | Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row |
| Aaron Wealth Advisors LLC | 1,175,771 SH | 68,923,696 dollars | Higher by 7,972 Prior quarter: 1,167,799 | Open filing 0001172661-26-004505 Filed 2026-10-13 Dispute this row |
| Driehaus Capital Management LLC | 1,012,698 SH | 59,364,357 dollars | Lower by 43,881 Prior quarter: 1,056,579 | Open filing 0000938206-26-000066 Filed 2026-11-16 Dispute this row |
| Kynam Capital Management, LP | 934,799 SH | 54,797,917 dollars | Unchanged Prior quarter: 934,799 | Open filing 0001907884-26-000017 Filed 2026-11-16 Dispute this row |
| EVENTIDE ASSET MANAGEMENT, LLC | 873,492 SH | 51,204,101 dollars | Unchanged Prior quarter: 873,492 | Open filing 0001580642-26-007711 Filed 2026-11-13 Dispute this row |
| STATE STREET CORP Partly reported under another manager | 861,502 SH | 50,501,247 dollars | Lower by 2,964 Prior quarter: 864,466 | Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row |
| GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager | 841,043 SH | 49,310,847 dollars | Higher by 67,971 Prior quarter: 773,072 | Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row |
| Parkman Healthcare Partners LLC | 716,542 SH | 42,003,692 dollars | Lower by 83,631 Prior quarter: 800,173 | Open filing 0001420506-26-002809 Filed 2026-11-16 Dispute this row |
| Woodline Partners LP | 653,972 SH | 38,335,839 dollars | Lower by 246,120 Prior quarter: 900,092 | Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row |
| TCG Crossover Management, LLC | 650,000 SH | 38,103,000 dollars | Unchanged Prior quarter: 650,000 | Open filing 0001214659-26-014306 Filed 2026-11-16 Dispute this row |
| Deep Track Capital, LP | 640,000 SH | 37,516,800 dollars | Lower by 1,092,569 Prior quarter: 1,732,569 | Open filing 0001856083-26-000006 Filed 2026-11-16 Dispute this row |
| PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager | 621,624 SH | 36,441 dollars | Lower by 193,183 Prior quarter: 814,807 | Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row |
| GOLDMAN SACHS GROUP INC Partly reported under another manager | 425,555 SH | 24,946,035 dollars | Lower by 33,450 Prior quarter: 459,005 | Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row |
| BRAIDWELL LP | 398,951 SH | 23,386,508 dollars | Lower by 311,929 Prior quarter: 710,880 | Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row |
| Cormorant Asset Management, LP Partly reported under another manager | 375,000 SH | 21,982,500 dollars | Lower by 175,000 Prior quarter: 550,000 | Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 323,459 SH | 18,961,167 dollars | Lower by 23,258 Prior quarter: 346,717 | Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row |
| LORD, ABBETT CO. LLC | 295,987 SH | 17,351 dollars | Not in the prior quarter’s filings read | Open filing 0000930413-26-003314 Filed 2026-11-13 Dispute this row |
| FRANKLIN TEMPLETON INC Partly reported under another manager | 293,217 SH | 15,388,028 dollars | Higher by 40,552 Prior quarter: 252,665 | Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row |
| Candriam S.C.A. | 281,493 SH | 16,561,409 dollars | Lower by 8,400 Prior quarter: 289,893 | Open filing 0001537014-26-000009 Filed 2026-11-03 Dispute this row |
| Rock Springs Capital Management LP | 275,347 SH | 16,140,841 dollars | Lower by 22,871 Prior quarter: 298,218 | Open filing 0001172661-26-005279 Filed 2026-11-16 Dispute this row |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 270,858 SH | 15,877,696 dollars | Higher by 37,763 Prior quarter: 233,095 | Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row |
| BANK OF AMERICA CORP /DE/ Partly reported under another manager | 266,783 SH | 15,638,820 dollars | Lower by 32,144 Prior quarter: 298,927 | Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row |
| NORTHERN TRUST CORP Partly reported under another manager | 262,138 SH | 15,366,530 dollars | Higher by 15,460 Prior quarter: 246,678 | Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row |
| Soleus Capital Management, L.P. | 258,897 SH | 15,176,542 dollars | Lower by 256,382 Prior quarter: 515,279 | Open filing 0001802630-26-000008 Filed 2026-11-16 Dispute this row |
| DIMENSIONAL FUND ADVISORS LP Partly reported under another manager | 232,413 SH | 13,624,050 dollars | Lower by 1,287 Prior quarter: 233,700 | Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row |
| UBS Group AG Partly reported under another manager | 227,768 SH | 13,351,760 dollars | Lower by 44,979 Prior quarter: 272,747 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
| Tetragon Partners GP Ltd | 220,647 SH | 12,934,327 dollars | Higher by 17,104 Prior quarter: 203,543 | Open filing 0000919574-26-008018 Filed 2026-11-16 Dispute this row |
| VANGUARD FIDUCIARY TRUST CO | 216,665 SH | 12,700,902 dollars | Higher by 15,236 Prior quarter: 201,429 | Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 202,461 SH | 11,868,290 dollars | Lower by 46,097 Prior quarter: 248,558 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| Schonfeld Strategic Advisors LLC | 158,104 SH | 9,268,056 dollars | Lower by 90,566 Prior quarter: 248,670 | Open filing 0001665241-26-000003 Filed 2026-11-16 Dispute this row |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager | 147,600 SH | 8,652,312 dollars | Higher by 53,200 Prior quarter: 94,400 | Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row |
| Invesco Ltd. Partly reported under another manager | 142,669 SH | 8,363,256 dollars | Higher by 91,991 Prior quarter: 50,678 | Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row |
| BARCLAYS PLC Partly reported under another manager | 136,652 SH | 8,010,541 dollars | Higher by 48,798 Prior quarter: 87,854 | Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 135,720 SH | 7,837,830 dollars | Lower by 3,891 Prior quarter: 139,611 | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
| D. E. Shaw Co., Inc. Partly reported under another manager | 127,305 SH | 7,462,619 dollars | Lower by 55,462 Prior quarter: 182,767 | Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row |
| KVP Capital Advisors, LP | 121,524 SH | 7,123,737 dollars | Unchanged Prior quarter: 121,524 | Open filing 0001104659-26-127594 Filed 2026-11-16 Dispute this row |
| MARSHALL WACE, LLP Partly reported under another manager | 113,023 SH | 6,625,408 dollars | Lower by 288,862 Prior quarter: 401,885 | Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 112,075 SH | 6,569,837 dollars | Lower by 1,400 Prior quarter: 113,475 | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| AMERIPRISE FINANCIAL INC Partly reported under another manager | 107,568 SH | 6,305,634 dollars | Not in the prior quarter’s filings read | Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row |
| Burkehill Global Management, LP | 100,000 SH | 5,862,000 dollars | Unchanged Prior quarter: 100,000 | Open filing 0001013594-26-001202 Filed 2026-11-16 Dispute this row |
| Bank of New York Mellon Corp Partly reported under another manager | 84,522 SH | 4,954,687 dollars | Lower by 4,405 Prior quarter: 88,927 | Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- EcoR1 Capital, LLC 388,500 SH
- Sixth Street Partners Management Company, L.P. 233,095 SH
- MILLENNIUM MANAGEMENT LLC 226,151 SH
- Caption Management, LLC 200,000 SH
- Caligan Partners LP 200,000 SH
- PFM Health Sciences, LP 70,971 SH
- OPTIMIZE FINANCIAL INC. 14,458 SH
- Sound Capital Solutions LLC 14,458 SH
- DAFNA Capital Management LLC 11,809 SH
- Jupiter Topco LLC 10,300 SH
- FRED ALGER MANAGEMENT, LLC 9,877 SH
- Brevan Howard Capital Management LP 8,602 SH
- ACT CAPITAL MANAGEMENT, LLC 8,000 SH
- AXQ CAPITAL, LP 7,757 SH
- XTX Topco Ltd 6,392 SH
- SG Americas Securities, LLC 6,245 SH
- INTECH INVESTMENT MANAGEMENT LLC 5,951 SH
- Blackstone Inc. 5,533 SH
- CANADA PENSION PLAN INVESTMENT BOARD 5,200 SH
- Verdad Advisers, LP 4,574 SH
- Goelzer Investment Management, Inc. 4,000 SH
- State of Wyoming 1,055 SH
- MERCER GLOBAL ADVISORS INC /ADV 553 SH
- Aster Capital Management (DIFC) Ltd 172 SH
- Integrated Wealth Concepts LLC 171 SH
- Quarry LP 18 SH
- NATIONAL BANK OF CANADA /FI/ 11 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share | 7.8 | 3,772,885.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-128295 Dispute this row |
| Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share | 7.8 | 3,772,885.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-128295 Dispute this row |
| Senai Asefaw, M.D. Common Stock, $0.0001 par value per share | 7.8 | 3,772,885.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-128295 Dispute this row |
| Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share | 6.9 | 3,324,531.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 1 | Open filing 0001104659-26-128295 Dispute this row |
| FMR LLC COMMON STOCK | 15.0 | 7,224,009.10 | 09/30/2026 Filed 2026-11-05 | SCHEDULE 13G/AAmendment 2 | Open filing 0000315066-26-002806 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 15.0 | 7,224,009.10 | 09/30/2026 Filed 2026-11-05 | SCHEDULE 13G/AAmendment 2 | Open filing 0000315066-26-002806 Dispute this row |
| ORBIMED ADVISORS LLC COMMON STOCK | 6.4 | 3,074,853.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0000947871-26-000776 Dispute this row |
| ORBIMED CAPITAL GP VII LLC COMMON STOCK | 5.2 | 2,505,150.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0000947871-26-000776 Dispute this row |
| ORBIMED GENESIS GP LLC COMMON STOCK | 1.2 | 569,703.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0000947871-26-000776 Dispute this row |
| Frazier Life Sciences Public Fund, L.P. Common Stock, $0.0001 par value per share | 3.0 | 1,429,573.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| FHMLSP, L.P. Common Stock, $0.0001 par value per share | 3.0 | 1,429,573.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| FHMLSP, L.L.C. Common Stock, $0.0001 par value per share | 3.0 | 1,429,573.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| Frazier Life Sciences X, L.P. Common Stock, $0.0001 par value per share | 10.8 | 5,219,440.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| FHMLS X, L.P. Common Stock, $0.0001 par value per share | 10.8 | 5,219,440.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| FHMLS X, L.L.C. Common Stock, $0.0001 par value per share | 10.8 | 5,219,440.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| Frazier Life Sciences XI, L.P. Common Stock, $0.0001 par value per share | 0.0 | 3,000.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| FHMLS XI, L.P. Common Stock, $0.0001 par value per share | 0.0 | 3,000.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| FHMLS XI, L.L.C. Common Stock, $0.0001 par value per share | 0.0 | 3,000.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| James N. Topper Common Stock, $0.0001 par value per share | 11.7 | 5,219,440.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| Patrick J. Heron Common Stock, $0.0001 par value per share | 11.7 | 5,243,421.00 | 08/06/2026 Filed 2026-08-10 | SCHEDULE 13D/AAmendment 3 | Open filing 0001231919-26-000851 Dispute this row |
| Deep Track Capital, LP Common Stock, $0.0001 par value per share | 3.64 | 1,732,569.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001172661-26-003482 Dispute this row |
| Deep Track Biotechnology Master Fund, Ltd. Common Stock, $0.0001 par value per share | 3.64 | 1,732,569.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001172661-26-003482 Dispute this row |
| David Kroin Common Stock, $0.0001 par value per share | 3.64 | 1,732,569.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001172661-26-003482 Dispute this row |
| BlackRock, Inc. Common Stock | 5.5 | 2,628,181 | 06/30/2026 Filed 2026-07-29 | SCHEDULE 13G | Open filing 0002012383-26-002818 Dispute this row |
| FMR LLC COMMON STOCK | 11.2 | 5,322,884.68 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0000315066-26-001474 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 11.2 | 5,322,884.68 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 1 | Open filing 0000315066-26-001474 Dispute this row |
| Wellington Management Group LLP Common Stock | 10.5 | 4,977,523.00 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 5 | Open filing 0000902219-26-000214 Dispute this row |
| Wellington Group Holdings LLP Common Stock | 10.5 | 4,977,523.00 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 5 | Open filing 0000902219-26-000214 Dispute this row |
| Wellington Investment Advisors Holdings LLP Common Stock | 10.5 | 4,977,523.00 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 5 | Open filing 0000902219-26-000214 Dispute this row |
| Wellington Management Company LLP Common Stock | 9.8 | 4,977,523.00 | 06/30/2026 Filed 2026-07-08 | SCHEDULE 13G/AAmendment 5 | Open filing 0000902219-26-000214 Dispute this row |
| Paradigm BioCapital Advisors LP Common Stock, $0.0001 par value per share | 5.2 | 2,493,015.00 | 06/16/2026 Filed 2026-06-24 | SCHEDULE 13G | Open filing 0001104659-26-077301 Dispute this row |
| Paradigm BioCapital Advisors GP LLC Common Stock, $0.0001 par value per share | 5.2 | 2,493,015.00 | 06/16/2026 Filed 2026-06-24 | SCHEDULE 13G | Open filing 0001104659-26-077301 Dispute this row |
| Senai Asefaw, M.D. Common Stock, $0.0001 par value per share | 5.2 | 2,493,015.00 | 06/16/2026 Filed 2026-06-24 | SCHEDULE 13G | Open filing 0001104659-26-077301 Dispute this row |
| Paradigm BioCapital International Fund Ltd. Common Stock, $0.0001 par value per share | 4.6 | 2,187,207.00 | 06/16/2026 Filed 2026-06-24 | SCHEDULE 13G | Open filing 0001104659-26-077301 Dispute this row |
| FMR LLC COMMON STOCK | 6.2 | 2,936,684.00 | 03/31/2026 Filed 2026-05-06 | SCHEDULE 13G | Open filing 0000315066-26-001256 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 6.2 | 2,936,684.00 | 03/31/2026 Filed 2026-05-06 | SCHEDULE 13G | Open filing 0000315066-26-001256 Dispute this row |
| BlackRock, Inc. Common Stock | 4.8 | 2,287,497 | 03/31/2026 Filed 2026-04-27 | SCHEDULE 13G/AAmendment 1 | Open filing 0002012383-26-001704 Dispute this row |
| ORBIMED ADVISORS LLC COMMON STOCK | 7.7 | 3,637,887.00 | 02/05/2026 Filed 2026-02-11 | SCHEDULE 13D/AAmendment 2 | Open filing 0000947871-26-000114 Dispute this row |
| ORBIMED CAPITAL GP VII LLC COMMON STOCK | 6.3 | 2,958,000.00 | 02/05/2026 Filed 2026-02-11 | SCHEDULE 13D/AAmendment 2 | Open filing 0000947871-26-000114 Dispute this row |
| OrbiMed Genesis GP LLC COMMON STOCK | 1.4 | 679,887.00 | 02/05/2026 Filed 2026-02-11 | SCHEDULE 13D/AAmendment 2 | Open filing 0000947871-26-000114 Dispute this row |
| Wellington Management Group LLP Common Stock | 7.5 | 3,349,961.00 | 12/31/2025 Filed 2026-02-10 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902219-26-000071 Dispute this row |
| Wellington Group Holdings LLP Common Stock | 7.5 | 3,349,961.00 | 12/31/2025 Filed 2026-02-10 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902219-26-000071 Dispute this row |
| Wellington Investment Advisors Holdings LLP Common Stock | 7.5 | 3,349,961.00 | 12/31/2025 Filed 2026-02-10 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902219-26-000071 Dispute this row |
| Wellington Management Company LLP Common Stock | 7.3 | 3,349,961.00 | 12/31/2025 Filed 2026-02-10 | SCHEDULE 13G/AAmendment 4 | Open filing 0000902219-26-000071 Dispute this row |
| BlackRock, Inc. Common Stock | 5.1 | 2,271,161 | 12/31/2025 Filed 2026-01-21 | SCHEDULE 13G | Open filing 0002012383-26-000690 Dispute this row |
| New Enterprise Associates 17, L.P. Common Stock, par value $0.0001 per share | 8.1 | 3,614,486.00 | 11/06/2025 Filed 2025-11-10 | SCHEDULE 13D/AAmendment 1 | Open filing 0001072613-25-000781 Dispute this row |
| NEA Partners 17, L.P. Common Stock, par value $0.0001 per share | 8.1 | 3,614,486.00 | 11/06/2025 Filed 2025-11-10 | SCHEDULE 13D/AAmendment 1 | Open filing 0001072613-25-000781 Dispute this row |
| NEA 17 GP, LLC Common Stock, par value $0.0001 per share | 8.1 | 3,614,486.00 | 11/06/2025 Filed 2025-11-10 | SCHEDULE 13D/AAmendment 1 | Open filing 0001072613-25-000781 Dispute this row |
| Forest Baskett Common Stock, par value $0.0001 per share | 8.1 | 3,614,486.00 | 11/06/2025 Filed 2025-11-10 | SCHEDULE 13D/AAmendment 1 | Open filing 0001072613-25-000781 Dispute this row |
| Ali Behbahani Common Stock, par value $0.0001 per share | 8.1 | 3,614,486.00 | 11/06/2025 Filed 2025-11-10 | SCHEDULE 13D/AAmendment 1 | Open filing 0001072613-25-000781 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,722,084 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 138,466 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,828 |
Filings made before the SEC required XML are listed, not extracted.